We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal imbalance. The firm's pipeline covers PRAX-114, fo... Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others. Show more
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 5, 2024 Registration No. 333- ...
As filed with the Securities and Exchange Commission on March 5, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...
FALSE000168954800016895482024-03-052024-03-05 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 8-K CURRENT REPORTPursuant to Section 13 or 15(d)of the...
false2023FY00016895480.06670.06670.06670.06670.0667http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2023#GeneralAndAdministrativeExpense00016895482023-01-012023-12...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 3.06 | 5.45065906662 | 56.14 | 67.21 | 50.25 | 309656 | 58.91031531 | CS |
4 | 11.7 | 24.6315789474 | 47.5 | 67.21 | 45.235 | 178081 | 56.55558452 | CS |
12 | 35.46 | 149.368155013 | 23.74 | 67.21 | 23.54 | 187110 | 45.36142211 | CS |
26 | 36.7 | 163.111111111 | 22.5 | 67.21 | 13.005 | 331250 | 26.68857149 | CS |
52 | 45.5665 | 334.224520483 | 13.6335 | 67.21 | 11.85 | 654280 | 19.903938 | CS |
156 | -405.8 | -87.2688172043 | 465 | 512.7 | 11.85 | 782088 | 63.59415373 | CS |
260 | -348.95 | -85.4955286047 | 408.15 | 914.2575 | 11.85 | 710890 | 86.40872286 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions